Global Alliance For Tb Drug Development Inc
Global Alliance For Tb Drug Development Inc consistently allocates 100% of reported officer compensation to programs, maintaining strong assets and stable operations.
EIN: 134128413 · New York, NY · NTEE: H80 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $202.5M |
| Total Expenses | $55.4M |
| Program Spending | 100% |
| CEO/Top Officer Pay | $50 |
| Net Assets | $171.7M |
| Transparency Score | 95/100 |
Is Global Alliance For Tb Drug Development Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Global Alliance For Tb Drug Development Inc directs 100% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Global Alliance For Tb Drug Development Inc
Global Alliance For Tb Drug Development Inc (EIN: 134128413) is a nonprofit organization based in New York, NY, classified under NTEE code H80. The organization reported total revenue of $202.5M and total assets of $204.3M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Global Alliance For Tb Drug Development Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Global Alliance For Tb Drug Development Inc is a major nonprofit that has been operating for 26 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 2.1%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $60.2M |
| Total Expenses | $55.4M |
| Surplus / Deficit | +$4.9M |
| Total Assets | $197.3M |
| Total Liabilities | $25.6M |
| Net Assets | $171.7M |
| Operating Margin | 8.1% |
| Debt-to-Asset Ratio | 13.0% |
| Months of Reserves | 42.8 months |
Financial Health Grade: A
In 2023, Global Alliance For Tb Drug Development Inc reported a surplus of $4.9M with revenue exceeding expenses, holds 42.8 months of operating reserves (strong position), has a debt-to-asset ratio of 13.0% (very low leverage).
Financial Trends
Over 13 years of filings (2011–2023), Global Alliance For Tb Drug Development Inc's revenue has grown at a compound annual growth rate (CAGR) of 2.1%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +7.2% | -0.7% | +11.7% |
| 2022 | -4.2% | -2.9% | -5.8% |
| 2021 | -4.3% | -7.0% | -1.9% |
| 2020 | -65.0% | -11.2% | +0.9% |
| 2019 | +176.3% | +15.3% | +152.0% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 8000 |
| IRS Ruling Date | 2000 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Global Alliance For Tb Drug Development Inc with a Mission Score of 95 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 0%
- programs: 100%
- fundraising: 0%
According to IRS 990 filings, Global Alliance For Tb Drug Development Inc allocates its expenses as follows: admin: 0%, programs: 100%, fundraising: 0%. With 100% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $4.9M, with revenue exceeding expenses.
- Debt-to-asset ratio: 13.0%.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, which is highly unusual for an organization of its size with annual expenses exceeding $50 million. This suggests that executive leadership may be compensated through other expense categories, or the organization operates with a unique leadership compensation structure.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Global Alliance For Tb Drug Development Inc's IRS 990 filings:
- Unusually low (0%) reported officer compensation, which may obscure actual executive remuneration if it's categorized elsewhere.
Strengths
The following positive indicators were identified for Global Alliance For Tb Drug Development Inc:
- Consistent financial health with revenues generally exceeding expenses.
- Strong and growing asset base, reaching $197,319,541 in 2023.
- Reported 0% officer compensation, indicating a strong focus on program spending.
- Effective management of significant revenue fluctuations, as seen in 2019.
- Low liabilities relative to assets, suggesting financial stability (e.g., $25,619,991 liabilities vs. $197,319,541 assets in 2023).
Frequently Asked Questions about Global Alliance For Tb Drug Development Inc
Is Global Alliance For Tb Drug Development Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Global Alliance For Tb Drug Development Inc (EIN: 134128413) some concerns. Mission Score: 95/100. 1 red flag identified, 5 strengths noted.
How does Global Alliance For Tb Drug Development Inc spend its money?
Global Alliance For Tb Drug Development Inc directs 100% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Global Alliance For Tb Drug Development Inc tax-deductible?
Global Alliance For Tb Drug Development Inc is registered as a tax-exempt nonprofit (EIN: 134128413). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How much does the Global Alliance For Tb Drug Development Inc CEO make?
Global Alliance For Tb Drug Development Inc's highest-compensated officer earns $50 annually. The organization reported $202.5M in total revenue. Executive compensation data is disclosed in IRS 990 filings.
How does Global Alliance For Tb Drug Development Inc compare to similar nonprofits?
With a transparency score of 95/100 (Excellent), Global Alliance For Tb Drug Development Inc is above average for NTEE category H80 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Global Alliance For Tb Drug Development Inc located?
Global Alliance For Tb Drug Development Inc is headquartered in New York, New York and files with the IRS under EIN 134128413. It is classified under NTEE code H80.
How many years of IRS 990 filings does Global Alliance For Tb Drug Development Inc have?
Global Alliance For Tb Drug Development Inc has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $202.5M in total revenue.
Is Global Alliance For Tb Drug Development Inc a good charity?
Based on the available IRS 990 data, Global Alliance For Tb Drug Development Inc appears to be a very good charity. It consistently maintains strong financial health, with revenues generally exceeding expenses, and a robust asset base. The reported 0% officer compensation is a significant positive indicator of mission focus.
How does Global Alliance For Tb Drug Development Inc fund its operations?
The organization primarily funds its operations through significant revenue streams, which have consistently been in the range of $50-60 million annually, with a notable spike to $174,873,899 in 2019. This suggests reliance on large grants, contributions, or other forms of public support.
What is the trend in Global Alliance For Tb Drug Development Inc's assets?
The organization's assets have shown consistent growth, particularly from $75,171,538 in 2018 to $197,319,541 in 2023, indicating strong financial management and accumulation of resources to support its mission.
Filing History
IRS 990 filing history for Global Alliance For Tb Drug Development Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Global Alliance For Tb Drug Development Inc's revenue has grown by 28.3%, moving from $46.9M to $60.2M. Total assets increased by 282.7% over the same period, from $51.6M to $197.3M. Total functional expenses rose by 50.7%, from $36.7M to $55.4M. In its most recent filing year (2023), Global Alliance For Tb Drug Development Inc reported a surplus of $4.9M, with revenue exceeding expenses. The organization holds $25.6M in liabilities against $197.3M in assets (debt-to-asset ratio: 13.0%), resulting in net assets of $171.7M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $60.2M | $55.4M | $197.3M | $25.6M | — | — |
| 2022 | $56.2M | $55.8M | $176.7M | $11.5M | — | View 990 |
| 2021 | $58.7M | $57.4M | $187.6M | $21.9M | — | View 990 |
| 2020 | $61.3M | $61.7M | $191.2M | $26.7M | — | — |
| 2019 | $174.9M | $69.5M | $189.4M | $24.7M | — | View 990 |
| 2018 | $63.3M | $60.3M | $75.2M | $15.8M | — | View 990 |
| 2017 | $58.0M | $56.1M | $73.0M | $16.4M | — | View 990 |
| 2016 | $53.0M | $54.0M | $83.1M | $28.5M | — | View 990 |
| 2015 | $61.3M | $57.8M | $105.0M | $49.4M | — | View 990 |
| 2014 | $45.9M | $43.2M | $87.0M | $34.7M | — | View 990 |
| 2013 | $46.1M | $40.6M | $71.9M | $22.0M | — | View 990 |
| 2012 | $46.3M | $42.6M | $58.1M | $13.9M | — | View 990 |
| 2011 | $46.9M | $36.7M | $51.6M | $11.0M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $60.2M, expenses of $55.4M, and assets of $197.3M (revenue +7.2% year-over-year).
- 2022: Revenue of $56.2M, expenses of $55.8M, and assets of $176.7M (revenue -4.2% year-over-year).
- 2021: Revenue of $58.7M, expenses of $57.4M, and assets of $187.6M (revenue -4.3% year-over-year).
- 2020: Revenue of $61.3M, expenses of $61.7M, and assets of $191.2M (revenue -65.0% year-over-year).
- 2019: Revenue of $174.9M, expenses of $69.5M, and assets of $189.4M (revenue +176.3% year-over-year).
- 2018: Revenue of $63.3M, expenses of $60.3M, and assets of $75.2M (revenue +9.1% year-over-year).
- 2017: Revenue of $58.0M, expenses of $56.1M, and assets of $73.0M (revenue +9.4% year-over-year).
- 2016: Revenue of $53.0M, expenses of $54.0M, and assets of $83.1M (revenue -13.4% year-over-year).
- 2015: Revenue of $61.3M, expenses of $57.8M, and assets of $105.0M (revenue +33.5% year-over-year).
- 2014: Revenue of $45.9M, expenses of $43.2M, and assets of $87.0M (revenue -0.5% year-over-year).
- 2013: Revenue of $46.1M, expenses of $40.6M, and assets of $71.9M (revenue -0.3% year-over-year).
- 2012: Revenue of $46.3M, expenses of $42.6M, and assets of $58.1M (revenue -1.5% year-over-year).
- 2011: Revenue of $46.9M, expenses of $36.7M, and assets of $51.6M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Global Alliance For Tb Drug Development Inc:
Data Sources and Methodology
This transparency report for Global Alliance For Tb Drug Development Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.